Interestingly, monoclonal antibodies and small-molecule inhibitors targeting CSF1R have been reported to result in a decreased number of TAMs and an increased ratio of CD8+/CD4+ T cells in the tumor (9, 202). This evidence concerns the gene CD8A and neoplasm.